Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Medicenna Therapeutics Corp
T.MDNA
Alternate Symbol(s):
MDNAF
Healthcare
Biotechnology
Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company's principal business activity is the development and commercialization of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL...
-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity, thereby preferentially stimulating cancer-killing effector T cells and NK cells. The Company’s IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials including a Phase IIb trial for recurrent glioblastoma (GBM). The Company’s early-stage Bifunctional SuperKine ImmunoTherapies (BiSKITs) program Targeted Metalloprotease Activated SuperKine (T-MASK) programs are designed to enhance the ability of Superkines to treat immunologically cold tumors.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:MDNA)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
Next
(580)
•••
Galaxym31
X
View Profile
View Bullboard History
Post by
Galaxym31
on Feb 29, 2024 2:55pm
Out with the weak eh .
.
(580)
•••
Galaxym31
X
View Profile
View Bullboard History
Comment by
Galaxym31
on Feb 26, 2024 11:57am
RE:RE:No volume , no stock . Is this company that tightly
Someone go in for a million shares . Do it .
(99)
•••
windymayor1
X
View Profile
View Bullboard History
Comment by
windymayor1
on Feb 26, 2024 10:05am
RE:No volume , no stock . Is this company that tightly
Hottest biotech in Cdn?! only took 2 years. Now can they re list on NASDAQ?
(580)
•••
Galaxym31
X
View Profile
View Bullboard History
Post by
Galaxym31
on Feb 26, 2024 9:57am
No volume , no stock . Is this company that tightly
held ? I think the powers that be no what this tech is worth now .
(580)
•••
Galaxym31
X
View Profile
View Bullboard History
Post by
Galaxym31
on Feb 25, 2024 11:43pm
Will this run hard tomorrow ?
.
(580)
•••
Galaxym31
X
View Profile
View Bullboard History
Post by
Galaxym31
on Feb 23, 2024 9:05pm
A 2 billion $ buyout is about 20 .00 US .
,
(99)
•••
windymayor1
X
View Profile
View Bullboard History
Comment by
windymayor1
on Feb 15, 2024 1:41pm
RE:Can we just shoot up to the last PP price , I think it
Great having 2 trials 11 & 55, News on a MDNA 55 partner for phase 3 would be nice as well. What's all this worth to Big Pharma if they hit on 2 drugs within the next year. $Bs
...more
(225)
•••
Alamir1111
X
View Profile
View Bullboard History
Comment by
Alamir1111
on Feb 15, 2024 11:52am
RE:Can we just shoot up to the last PP price , I think it
Galaxy nice Goodluck Enjoy
(580)
•••
Galaxym31
X
View Profile
View Bullboard History
Post by
Galaxym31
on Feb 15, 2024 10:39am
Can we just shoot up to the last PP price , I think it
was 1.50 US . TIA
(120)
•••
ENEMENEMYNEMO
X
View Profile
View Bullboard History
Comment by
ENEMENEMYNEMO
on Feb 15, 2024 8:32am
RE:I like this .
Keytruda 30 billion/yr sales. Patent expires 2028. Merck needs a reformulation. Addition of MDMA-11 (if trial shows success) as a combination drug would give Merck an extra 20 years
...more
(580)
•••
Galaxym31
X
View Profile
View Bullboard History
Post by
Galaxym31
on Feb 15, 2024 12:15am
I like this .
The global multi-arm Phase 1/2 ABILITY-1 study is expanding to various cancer centers in the US, Canada, Australia, South Korea and Europe evaluating MDNA11 as a single-agent and in combination with
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Feb 14, 2024 7:30am
New Press Release - Medicenna Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Corporate Update
With the Response Rate increasing to 23%, MDNA11 continues to show compelling single-agent activity in the ABILITY-1 study amongst high-dose phase-2 eligible patients (N=13) that failed checkpoint inhibitor therapies, while maintaining an acceptable safety profile Tumor shrinkage was also...
read article.
(580)
•••
Galaxym31
X
View Profile
View Bullboard History
Post by
Galaxym31
on Feb 13, 2024 9:54pm
What type of cancer does the patient have ?
Might give hope to others .
(580)
•••
Galaxym31
X
View Profile
View Bullboard History
Post by
Galaxym31
on Feb 13, 2024 9:18pm
Long road and big moment for the MDNA team .
Go Canada .
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Feb 13, 2024 7:00am
New Press Release - Medicenna Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
The ABILITY-1 Study is evaluating MDNA11, a highly selective long-acting IL-2 Superkine, in combination with KEYTRUDA® (pembrolizumab) for treatment of patients with advanced solid tumorsMDNA11 continues to demonstrate encouraging single-agent activity from the monotherapy dose escalation portion...
read article.
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Options Trading for Retiring: Key Strategies in Balancing Retirement Income
One Property, One Focus on Advancing this Gold Project in Ontario